# Aripiprazole

## Abilify Maintena inj 400mg

| TAH Drug Code      | [IABI](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IABI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treating schizophrenia in adults. Monotherapy for maintenance treatment of adult type I bipolar disorder.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | 400 mg once monthly (doses should be separated by more than 26 days); Tolerability should be established using oral aripiprazole prior to initiation of parenteral therapy; due to the half-life of oral aripiprazole it may take up to 2 weeks to fully assess tolerability. Continue oral aripiprazole (or other oral antipsychotic) for 14 days during initiation of parenteral therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Contraindications  | Hypersensitivity to aripiprazole or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Adverse Effects    | Common: Injection site pain (5-19%), Weight increased, 7% or greater (2.2-26.3%), Constipation (5-11%), Decrease in appetite (7%), Excessive salivation ( 4%), Increased appetite (3-7%), Nausea (8-15%), Vomiting (3-11%), Akathisia (2-25%), Dizziness (4-10%), Extrapyramidal disease (2-27.3%), Headache (10-27%), Insomnia (8-18%), Lethargy (5%), Sedated (3-21%), Somnolence (6-26.3%), Tremor (2-11.8%), Blurred vision (3-8%), Anxiety (4-17%), Restlessness (2-12%), Nasopharyngitis (3-9%), Fatigue (2-17%) Serious: Cardiorespiratory arrest (0.1-1%), Cardiorespiratory failure (Up to 0.1%), Myocardial infarction (Up to 0.1%), Myocardial ischemia (Up to 0.1%), Orthostatic hypotension (0.2-1%), Prolonged QT interval (Up to 0.1%), Diabetic ketoacidosis, Hyperglycemia (0.8-8%), Dysphagia, Pancreatitis, Agranulocytosis, Leukopenia, Neutropenia (5.7%), Rhabdomyolysis (Up to 0.1%), Seizure (Up to 0.1%), Tardive dyskinesia (Pediatric, 1.7%), At increased risk for suicide, Compulsive gambling, Suicidal behavior, Angioedema, Increased body temperature, Neuroleptic malignant syndrome |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| More Info          | [UpToDate](https://www.uptodate.com/contents/aripiprazole-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

## Abilify 5mg

| TAH Drug Code      | [OABI](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OABI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Schizophrenia in adults & adolescents 13-17 years. Monotherapy or adjunctive therapy to either lithium or valproate for the acute manic & mixed episodes associated with Bipolar I disorder in adults & pediatrics 10-17 years. Adjunctive treatment of major depressive disorders. Irritability associated with autistic disorder in pediatric patients 6-17 years. Tourette's syndrome.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Dosing             | Schizophrenia: Adults: 10mg or 15mg QD. Effective range: 10-30 mg/day. Do not increase the dose until the course of treatment is up to 2 weeks. Teenagers, 13-17 years old: The initial daily dose is 2 mg, and it will be adjusted to 5 mg after 2 days, and then adjusted to the target dose of 10 mg after another 2 days. Bipolar disorder manic episodes and mixed episodes: Adults: 15mg QD. The initial dose for adjuvant therapy of lithium or valproate is 10-15 mg/day. Can be increased to 30 mg/day based on clinical response. Children, 10-17 years old: The initial daily dose is 2 mg, and adjusted to 5 mg after 2 days, and then adjusted to the target dose of 10 mg after another 2 days. If necessary after the adjustment, the dose should be increased by 5 mg each time. Adjuvant treatment of major depression: Adults: Inintial dose:2-5mg/day, titrate the dose to 10 mg/day or 15 mg/day in a manner not exceeding 5 mg/day each time. The adjustment interval should be more than 1 week. Tourette syndrome, 6~18 years old: <50kg: The initial dose is 2 mg per day, and the target dose of 5 mg/day will be reached after two days. In patients whose tics are not well controlled, the dose can be increased to 10 mg/day. The dosage should be adjusted step by step not to exceed 5 mg/day each time, and the interval should not be less than 1 week. >50kg: The initial dose is 2 mg/day for 2 days, then the dose is increased to 5 mg/day for 5 days, and the target dose is 10 mg/day on the 8th day. In patients whose tics are not well controlled, the dose can be increased to 20 mg/day. The dose should be adjusted step by step not to exceed 5 mg/day each time, and the interval should not be less than 1 week. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Known hypersensitivity to aripiprazole.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | Common: Weight increased, 7% or greater (2.2-26.3%), Constipation (5-11%), Decrease in appetite (7%), Excessive salivation ( 4%), Increased appetite (3-7%), Nausea (8-15%), Vomiting (3-11%), Akathisia (2-25%), Dizziness (4-10%), Extrapyramidal disease (2-27.3%), Headache (10-27%), Insomnia (8-18%), Lethargy (5%), Sedated (3-21%), Somnolence (6-26.3%), Tremor (2-11.8%), Blurred vision (3-8%), Anxiety (4-17%), Restlessness (2-12%), Nasopharyngitis (3-9%), Fatigue (2-17%) Serious: Cardiorespiratory arrest (0.1-1%), Cardiorespiratory failure (Up to 0.1%), Myocardial infarction (Up to 0.1%), Myocardial ischemia (Up to 0.1%), Orthostatic hypotension (0.2-1%), Prolonged QT interval (Up to 0.1%), Diabetic ketoacidosis, Hyperglycemia (0.8-8%), Dysphagia, Pancreatitis, Agranulocytosis, Leukopenia, Neutropenia (5.7%), Rhabdomyolysis (Up to 0.1%), Seizure (Up to 0.1%), Tardive dyskinesia (Pediatric, 1.7%), At increased risk for suicide, Compulsive gambling, Suicidal behavior, Angioedema, Increased body temperature, Neuroleptic malignant syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Pregnancy          | Human Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| More Info          | [UpToDate](https://www.uptodate.com/contents/aripiprazole-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

